No parent wants to see their child suffer - much less suffer from allergies.

Thank you for your interest in the UCB allergic rhinitis or chronic urticaria clinical studies. We are currently conducting two clinical studies ranging in age from 6 months to 6 years. Both studies have trial centers across the country and are being conducted by Board Certified physicians.

To learn if your child qualifies to participate in one of the 2 the allergic rhinitis or chronic urticaria clinical trials you may complete our pre-screening questionnaire. This can be done by answering the questions below or, if you would like to speak to a live operator, you can call our toll-free call center number at: 877-997-8839.

The goal of these clinical studies is to determine the safety of an oral liquid formulation of a FDA approved allergy medication (an antihistamine) called levocetirizine dihydrochloride in children ages 6 months to 6 years who have symptoms of or have been diagnosised with allergic rhinitis or chronic urticaria. This product is FDA approved and currently available on the market for adults and children ages 6 and up. . However, there is a higher chance of your child receiving levocetirizine dihydrochloride due to the fact that the dosing ratio is set up so that for every 2 study subjects for receive levocetirizine dihydrochloride, only 1 will receive placebo.

This is a randomized, blinded study, which means everyone who participates will be assigned to one of two groups; one group will receive levocetirizine dihydrochloride and one group will receive placebo (which is not the active study drug). A random selection process will decide the group assignments. In the study everyone will be assigned to one group or the other by chance.

To determine if your child qualifies for this clinical study, you will have a screening visit at the doctor's office at which time they will evaluate your child's physical health, draw blood for laboratory tests and perform an ECG (electronic monitoring of your child's heart activity). If your child qualifies at this visit and participates in this study, the participation will involve an additional 3 office visits and possibly a follow-up phone call. The entire study duration will last a minimum of 16 days and a maximum of 7 weeks.

All study-related medical exams and laboratory tests are provided to qualified participants at no cost.

The following medical questions will be used to determine if your child may be eligible for this study. This is the first step in qualifying for this study. Some tests will also need to be completed at the clinical study site to determine if your child will definitely qualify to participate in this study. Please understand that answering these questions is voluntary. You do not have to answer any questions you do not want to answer and you may stop at any time. If the questionnaire is incomplete, it may be disqualified and your child may not be considered for participation in the stud. If all the questions are answered, the questionnaire will be forwarded to the clinical trial site you have chosen. The Study Coordinator at that site will contact you to provide additional trial information and discuss your questionnaire in more detail, if needed.

This pre-screening questionnaire is used to determine if your child is eligible for further screening at the clinical trial site. There is no guarantee that your child will be selected to participate. Only the clinical trial doctor can determine if your child is eligible to participate in this trial after your child has completed a study screening visit, specific testing, and a clinical evaluation. If, based on the information you provide to us, you are not qualified for this clinical trial, your information will not be forwarded to the Study Coordinator and will be destroyed.